candesartan has been researched along with Cardiac Hypertrophy in 30 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Many lines of evidence have suggested that angiotensin II (Ang II) plays a vital role in cardiac hypertrophy, and it has been reported that secretion of Ang II from cultured cardiac myocytes was induced by mechanical stretch." | 7.69 | Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. ( Hiroi, Y; Komuro, I; Kudoh, S; Mizuno, T; Shiojima, I; Takano, H; Tobe, K; Ueki, K; Yamazaki, T; Zou, Y, 1995) |
| "The angiotensin II (AngII) type 1 (AT1) receptor is a seven transmembrane-spanning G-protein-coupled receptor, and the activation of AT1 receptor plays an important role in the development of load-induced cardiac hypertrophy." | 4.84 | A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. ( Akazawa, H; Komuro, I; Qin, Y; Yasuda, N; Zou, Y, 2008) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| " Here we compared the effects of five commonly used ARBs (Candesartan, Olmesartan, Losartan, Telmisartan and Valsartan) on pressure overload-induced cardiac hypertrophy in mice model." | 3.76 | Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. ( Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y, 2010) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "The angiotensin II type 1 (AT1) receptor has a crucial role in load-induced cardiac hypertrophy." | 3.72 | Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. ( Akazawa, H; Fujita, T; Fukamizu, A; Iiri, T; Iwanaga, K; Kihara, M; Komuro, I; Kudoh, S; Makita, N; Minamino, T; Nagai, T; Qin, Y; Sano, M; Takano, H; Tamura, K; Toko, H; Umemura, S; Zhu, W; Zou, Y, 2004) |
| "The possible role of calcineurin in the attenuation of cardiac hypertrophy and fibrosis by blockade of the angiotensin II type 1 (AT1) receptor was investigated in Dahl salt-sensitive (DS) rats." | 3.71 | AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. ( Ichihara, S; Iwase, M; Izawa, H; Nagasaka, T; Nagata, K; Nakashima, N; Obata, K; Odashima, M; Somura, F; Yamada, Y; Yokota, M, 2002) |
| " Chronic treatment with enalapril or candesartan inhibited the development of hypertension and cardiac hypertrophy equally in SHR." | 3.71 | Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats. ( Harada, S; Hatta, T; Kawa, T; Kido, H; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Oguni, A; Sasaki, S; Takeda, K, 2002) |
| " Many lines of evidence have suggested that angiotensin II (Ang II) plays a vital role in cardiac hypertrophy, and it has been reported that secretion of Ang II from cultured cardiac myocytes was induced by mechanical stretch." | 3.69 | Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. ( Hiroi, Y; Komuro, I; Kudoh, S; Mizuno, T; Shiojima, I; Takano, H; Tobe, K; Ueki, K; Yamazaki, T; Zou, Y, 1995) |
| "Candesartan-pretreated SHHF (5 mg/kg/day candesartan; weeks 4-8) received during adulthood (20-28 weeks of age) either candesartan at a dose of 1." | 1.36 | Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment. ( Baumann, M; Heemann, U; Lutz, J; Roos, M; Sollinger, D, 2010) |
| "Chronic isoproterenol (ISO)-induced cardiac hypertrophy was inhibited in wild-type mice and AT1aR(-/-) mice treated with the ARB Candesartan (CV11974)." | 1.36 | Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors. ( Kimura, S; Matsuyoshi, H; Murao, K; Obata, K; Takaki, M; Yu, X; Zhang, GX, 2010) |
| "Pressure overload induced cardiac hypertrophy in angiotensinogen null mice as well as in wild-type mice, which was significantly inhibited by candesartan." | 1.33 | A novel mechanism of mechanical stress-induced hypertrophy. ( Akazawa, H; Komuro, I; Zou, Y, 2006) |
| "Candesartan treatment decreased cardiac PAI-1 expression only in the dark in WKY rats but throughout the day in SHR." | 1.32 | Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. ( Fujioka, Y; Iwasaki, T; Kawasaki, D; Masai, M; Morimoto, S; Naito, Y; Ohyanagi, M; Okumura, T; Sakoda, T; Tsujino, T, 2003) |
| "Also, low-dose perindopril prevented cardiac hypertrophy and fibrosis." | 1.32 | Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. ( Horikoshi, K; Izumi, T; Mochizuki, S; Nagai, M; Seki, S; Taniguchi, I; Taniguchi, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohkura, SI | 1 |
| Usui, S | 1 |
| Takashima, SI | 1 |
| Takuwa, N | 1 |
| Yoshioka, K | 1 |
| Okamoto, Y | 1 |
| Inagaki, Y | 1 |
| Sugimoto, N | 1 |
| Kitano, T | 1 |
| Takamura, M | 1 |
| Wada, T | 1 |
| Kaneko, S | 1 |
| Takuwa, Y | 1 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Suzuki, H | 1 |
| Katanasaka, Y | 1 |
| Sunagawa, Y | 1 |
| Miyazaki, Y | 1 |
| Funamoto, M | 1 |
| Wada, H | 1 |
| Hasegawa, K | 1 |
| Morimoto, T | 1 |
| Nakamura, K | 1 |
| Koibuchi, N | 1 |
| Nishimatsu, H | 1 |
| Higashikuni, Y | 1 |
| Hirata, Y | 2 |
| Kugiyama, K | 1 |
| Nagai, R | 2 |
| Sata, M | 1 |
| Takahara, A | 1 |
| Nakamura, Y | 1 |
| Wagatsuma, H | 1 |
| Aritomi, S | 1 |
| Nakayama, A | 1 |
| Satoh, Y | 1 |
| Akie, Y | 1 |
| Sugiyama, A | 1 |
| Baumann, M | 1 |
| Sollinger, D | 1 |
| Roos, M | 1 |
| Lutz, J | 1 |
| Heemann, U | 1 |
| Ocaranza, MP | 1 |
| Lavandero, S | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Pinto, M | 1 |
| Novoa, U | 1 |
| Apablaza, F | 1 |
| Gonzalez, L | 1 |
| Hernandez, C | 1 |
| Varas, M | 1 |
| Lopez, R | 1 |
| Godoy, I | 1 |
| Verdejo, H | 1 |
| Chiong, M | 1 |
| Zhang, GX | 1 |
| Kimura, S | 1 |
| Murao, K | 1 |
| Yu, X | 1 |
| Obata, K | 2 |
| Matsuyoshi, H | 1 |
| Takaki, M | 1 |
| Li, L | 1 |
| Zhou, N | 1 |
| Gong, H | 1 |
| Wu, J | 1 |
| Lin, L | 1 |
| Komuro, I | 8 |
| Ge, J | 1 |
| Zou, Y | 7 |
| Shimizu, T | 1 |
| Hirayama, H | 1 |
| Hiramitsu, S | 1 |
| Shimizu, K | 1 |
| Yoshida, O | 1 |
| Miao, CY | 1 |
| Xie, HH | 1 |
| Wang, JJ | 1 |
| Su, DF | 1 |
| Nagata, K | 1 |
| Somura, F | 1 |
| Odashima, M | 1 |
| Izawa, H | 1 |
| Ichihara, S | 1 |
| Nagasaka, T | 1 |
| Iwase, M | 1 |
| Yamada, Y | 1 |
| Nakashima, N | 1 |
| Yokota, M | 1 |
| Yayama, K | 1 |
| Matsuoka, S | 1 |
| Nagaoka, M | 1 |
| Shimazu, E | 1 |
| Takano, M | 1 |
| Okamoto, H | 1 |
| Naito, Y | 1 |
| Tsujino, T | 1 |
| Kawasaki, D | 1 |
| Okumura, T | 1 |
| Morimoto, S | 2 |
| Masai, M | 1 |
| Sakoda, T | 1 |
| Fujioka, Y | 1 |
| Ohyanagi, M | 1 |
| Iwasaki, T | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Akazawa, H | 3 |
| Qin, Y | 2 |
| Sano, M | 2 |
| Takano, H | 3 |
| Minamino, T | 2 |
| Makita, N | 1 |
| Iwanaga, K | 1 |
| Zhu, W | 1 |
| Kudoh, S | 4 |
| Toko, H | 1 |
| Tamura, K | 1 |
| Kihara, M | 1 |
| Nagai, T | 1 |
| Fukamizu, A | 1 |
| Umemura, S | 1 |
| Iiri, T | 1 |
| Fujita, T | 1 |
| Nagai, M | 1 |
| Horikoshi, K | 1 |
| Izumi, T | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Iwashima, Y | 1 |
| Okada, M | 1 |
| Haneda, M | 1 |
| Yoshida, T | 1 |
| Okazaki, H | 1 |
| Tsukamoto, O | 1 |
| Kim, J | 1 |
| Okada, K | 1 |
| Myoishi, M | 1 |
| Wakeno, M | 1 |
| Takashima, S | 1 |
| Mochizuki, N | 1 |
| Kitakaze, M | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Yoneda, T | 1 |
| Usukura, M | 1 |
| Takata, H | 1 |
| Yamagishi, M | 1 |
| Yasuda, N | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Yamazaki, T | 3 |
| Shiojima, I | 2 |
| Mizuno, T | 2 |
| Hiroi, Y | 2 |
| Ueki, K | 1 |
| Tobe, K | 1 |
| Kanno, K | 1 |
| Eguchi, S | 1 |
| Kano, H | 1 |
| Maemura, K | 1 |
| Kurihara, H | 1 |
| Aikawa, R | 2 |
| Yazaki, Y | 2 |
| Kodama, H | 1 |
| Fukuda, K | 1 |
| Pan, J | 1 |
| Makino, S | 1 |
| Takahashi, T | 1 |
| Hori, S | 1 |
| Ogawa, S | 1 |
| Harada, M | 1 |
| Saito, Y | 1 |
| Nakagawa, O | 1 |
| Miyamoto, Y | 1 |
| Ishikawa, M | 1 |
| Kuwahara, K | 1 |
| Ogawa, E | 1 |
| Nakayama, M | 1 |
| Kamitani, S | 1 |
| Hamanaka, I | 1 |
| Kajiyama, N | 1 |
| Masuda, I | 1 |
| Itoh, H | 1 |
| Tanaka, I | 1 |
| Nakao, K | 1 |
| Uozumi, H | 1 |
| Miki, S | 1 |
| Takeda, K | 1 |
| Hatta, T | 1 |
| Harada, S | 1 |
| Kido, H | 1 |
| Oguni, A | 1 |
| Moriguchi, J | 1 |
| Kawa, T | 1 |
| Sasaki, S | 1 |
| Nakagawa, M | 1 |
1 review available for candesartan and Cardiac Hypertrophy
| Article | Year |
|---|---|
A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2008 |
1 trial available for candesartan and Cardiac Hypertrophy
| Article | Year |
|---|---|
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
28 other studies available for candesartan and Cardiac Hypertrophy
| Article | Year |
|---|---|
Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compound | 2017 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; | 2016 |
Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice.
Topics: Age Factors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Topics: Action Potentials; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atr | 2009 |
Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Benzi | 2010 |
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2010 |
Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors.
Topics: Adrenergic beta-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natr | 2010 |
[Drug therapies following heart failure and myocardial infarction(discussion)].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl | 2002 |
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2002 |
Down-regulation of bradykinin B2-receptor mRNA in the heart in pressure-overload cardiac hypertrophy in the rat.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Cardiom | 2003 |
Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; ARNTL Transcriptio | 2003 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2004 |
Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2006 |
A novel mechanism of mechanical stress-induced hypertrophy.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Chlorocebus aethiops; COS Cells; Enzyme A | 2006 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardi | 1995 |
Effect of an AT1 receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocyte hypertrophy in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blott | 1994 |
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy.
Topics: Animals; Animals, Newborn; Antibodies; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Depend | 1996 |
Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardi | 1998 |
Role of cardiac nonmyocytes in cyclic mechanical stretch-induced myocyte hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compo | 1997 |
Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Dependent Protein Ki | 1998 |
Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2002 |